This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.—
To the response of J. Richard Crout, MD, of the Bureau of Drugs (234:480, 1975) to the comment of Dr Freis (229:689, 1974) that "the Food and Drug Administration (FDA) is depriving American physicians and patients of useful hypertensive drugs," may I add the following.For the past three years, I have been a member of the panel of ophthalmic device classification of the FDA. This has necessitated many trips during the year to Washington, a close liason with the FDA and with other members of other panels dealing with drugs, and other devices.I can only say that I was most pleased with the total cooperation shown by government officials in all aspects of evaluating drugs and devices, bending backwards to give the manufacturer and public a break in interpretation of rules, but all within the framework of the law as it is spelled out. One
Wainstock MA. FDA Defended. JAMA. 1976;235(13):1327. doi:10.1001/jama.1976.03260390013011
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: